Heterotransplant mouse model cohorts of human malignancies: A novel platform for Systematic Preclinical Efficacy Evaluation of Drugs (SPEED)

American Journal of Translational Research

Volumn 1, Issue 1, 2009, Pages 16-22

  Pathak, Ashutosh K ^a,c   Bhutani, Manisha ^a,b   Saintigny, Pierre ^a   Mao, Li ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b MICHIGAN STATE UNIVERSITY   (United States)

^c BRISTOL MYERS SQUIBB   (United States)

Author keywords

Animal model; Cancer; Drug development; Heterotransplant; Therapeutics

Indexed keywords

DRUG;

CANCER INHIBITION; CANCER MODEL; CANCER RESISTANCE; DRUG EFFICACY; DRUG RESEARCH; DRUG SENSITIVITY; EXPERIMENTAL MOUSE; LUNG NON SMALL CELL CANCER; MOUSE; NONHUMAN; REVIEW; TUMOR XENOGRAFT; XENOTRANSPLANTATION;

ANIMALIA;

EID: 77953430456     PISSN: None     EISSN: 19438141     Source Type: Journal    
DOI: None     Document Type: Review

References (22)

1. Owens J: 2006 drug approvals: finding the niche. Nat Mullin R: Drug Discov 2007;6:99-101.
2. Mullin R: Drug development costs about $1.7 billion. Chem. Eng. News 81, 2003
3. Kola I, Landis J: Can the pharmaceutical industry reduce attrition rates? Nat Rev Drug Discov 2004;3:711-5.
4. Elias TG, M. Singh, N. & Zemmel, R.: Why products fail in phase III. in vivo 2006;24:49-54.
5. Kola I: The state of innovation in drug development. Clin Pharmacol Ther 2008; 83:227-30.
6. Betensky RA, Louis DN, Cairncross JG: Influence of unrecognized molecular heterogeneity on randomized clinical trials. J Clin Oncol 2002;20:2495-9.
7. Kopetz S, Overman M, Chang DZ, Glover KY, Shureiqi I, Wolff RA, Abbruzzese JL, Eng C: Systematic survey of therapeutic trials for metastatic colorectal cancer: room for improvement in the critical pathway. J Clin Oncol 2008;26:2000-5.
8. Benson AB, 3rd: From silos to a critical path of new agent development: a paradigm to revolutionize clinical research. J Clin Oncol 2008;26:1924-5.
9. Mandrekar SJ, Grothey A, Goetz MP, Sargent DJ: Clinical trial designs for prospective validation of biomarkers. Am J Pharmacogenomics 2005;5:317-25.
10. Sargent DJ, Conley BA, Allegra C, Collette L: Clinical trial designs for predictive marker validation in cancer treatment trials. J Clin Oncol 2005;23:2020-7.
11. Gilbert J HP, Singh A: Rebuilding Big Pharma's Business Model. in Vivo 21, 2003
12. Consortium: Genome sequence of the Brown Norway rat yields insights into mammalian evolution. Nature 2004;428:493-521.
13. Salmon SE, Hamburger AW, Soehnlen B, Durie BG, Alberts DS, Moon TE: Quantitation of differential sensitivity of human-tumor stem cells to anticancer drugs. N Engl J Med 1978;298:1321-7.
14. Sanfilippo O, Daidone MG, Costa A, Canetta R, Silvestrini R: Estimation of differential in vitro sensitivity of non-Hodgkin lymphomas to anticancer drugs. Eur J Cancer 1981;17:217-26.
15. Gazdar AF, Steinberg SM, Russell EK, Linnoila RI, Oie HK, Ghosh BC, Cotelingam JD, Johnson BE, Minna JD, Ihde DC: Correlation of in vitro drug-sensitivity testing results with response to chemotherapy and survival in extensive-stage small cell lung cancer: a prospective clinical trial. J Natl Cancer Inst 1990;82:117-24.
16. Fruehauf JP BA: In vitro determination of drug response: A discussion of clinical applications, in DeVita VT Jr HS, Rosenberg SA (eds) Principles and Practice of Oncology Updates (ed 4). Philadelphia, PA, JB Lippincott,, 1993, p 1-16
17. Poupon MF, Arvelo F, Goguel AF, Bourgeois Y, Jacrot M, Hanania N, Arriagada R, Le Chevalier T: Response of small-cell lung cancer xenografts to chemotherapy: multidrug resistance and direct clinical correlates. J Natl Cancer Inst 1993;85:2023-9.
18. Shaw GL, Gazdar AF, Phelps R, Linnoila RL, Ihde DC, Johnson BE, Oie HK, Pass HI, Steinberg HM, Ghosh BC, Walsh TE, Nesbitt JC, Cotelingam JD, Minna JD, and Mulshine JL: Individualized chemotherapy for patients with non-small cell lung cancer determined by prospective identification of neuroendocrine markers and in vitro drug sensitivity testing. Cancer Res 1993;53:5181-7.
19. Fiebig HH, Maier A, Burger AM: Clonogenic assay with established human tumour xenografts: correlation of in vitro to in vivo activity as a basis for anticancer drug discovery. Eur J Cancer 2004;40:802-20.
20. Perez-Soler R, Kemp B, Wu QP, Mao L, Gomez J, Zeleniuch-Jacquotte A, Yee H, Lee JS, Jagirdar J, Ling YH: Response and determinants of sensitivity to paclitaxel in human non-small cell lung cancer tumors heterotransplanted in nude mice. Clin Cancer Res 2000;6:4932-8.
21. Rubio-Viqueira B, Jimeno A, Cusatis G, Zhang X, Iacobuzio-Donahue C, Karikari C, Shi C, Danenberg K, Danenberg PV, Kuramochi H, Tanaka K, Singh S, Salimi-Moosavi H, Bouraoud N, Amador ML, Altiok S, Kulesza P, Yeo C, Messersmith W, Eshleman J, Hruban RH, Maitra A, Hidalgo M: An in vivo platform for translational drug development in pancreatic cancer. Clin Cancer Res 2006;12:4652-61.
22. Castro M: The simpleton's error in drug development. J Clin Oncol 2002;20:4606-7.